Nonmedical influences on the use of cholinesterase inhibitors in dementia care

Alzheimer Disease and Associated Disorders

Volumn 21, Issue 3, 2007, Pages 241-248

  Franz, Carol E ^a   Barker, Judith C ^b   Kravitz, Richard L ^c   Flores, Yvette ^c   Krishnan, Sheila ^c   Hinton, Ladson ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cholinesterase inhibitors; Cognitive enhancers; Dementia treatment; Primary care

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL;

ADULT; AGED; ARTICLE; DEMENTIA; DRUG USE; EXPERIENCE; FEMALE; HEALTH PERSONNEL ATTITUDE; HUMAN; KNOWLEDGE; MALE; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; PATIENT CARE; PHYSICIAN; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITATIVE RESEARCH;

ADULT; AGED; ATTITUDE OF HEALTH PERSONNEL; CHOLINESTERASE INHIBITORS; CLINICAL COMPETENCE; CROSS-SECTIONAL STUDIES; DECISION MAKING; DEMENTIA; FEMALE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, FAMILY; TREATMENT OUTCOME;

EID: 34548416648     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e3181461955     Document Type: Article

References (50)

1. Iffle S, Eden A, Downs M, et al. The diagnosis and management of dementia in primary care: development, implementation, and evaluation of a national training programme. Aging Ment Health. 1999;3:129-135.
2. Van Hout H, Vernooij-Dassen M, Bakker K, et al. General practitioners on dementia: tasks, practices, and obstacles. Patient Educ Couns. 2000;39:219-225.
3. Ganguli M, Rodriguez E, Mulsant B, et al. Detection and management of cognitive impairment in primary care: The Steel Valley Seniors Survey. J Am Geriatr Soc. 2004;52:1668-1675.
4. Grembowski DE, Cook KS, Patrick DL, et al. Managed care and the US health care system: a social exchange perspective. Soc Sci Med. 2002;54:1167-1180.
5. Wolff LE, Woods JP, Reid J. Do general practitioners and old-age psychiatrists differ in their attitudes toward dementia. Int J Geriatr Psychiatry. 1995;10:63-69.
6. Graham J. Harbinger of hope or commodity fetishism: "re- cognizing" dementia in an age of therapeutic agents. Int Psychogeriatr. 2001;13:131-134.
7. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333-1341.
8. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;9:2379-2388.
9. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000); randomised double-blind trial. Lancet. 2004;363:2105-2115.
10. Wimo A, Winblad B, Shah SN, et al. Impact of donepezil treatment for Alzheimer's disease on caregiver time. Curr Med Res Opin. 2004;20:1221-1225.
11. Ballard C, Margallo-Lana M, Juszczak E, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimers' disease. BMJ. 2005;330:874-877.
12. Birks J, Flicker L. Donepezil for mild cognitive impairment. Cochrane Database Sys Rev. 2006;(3):CD006104.
13. Birks J, Harvey R. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Sys Rev. 2006;25:CD001190.
14. Kaduszkiewicz H, Zimmerman T, Beck-Bernholdt H, et al. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ. 2006;331:321-327.
15. Lu S, Hill J, Fillit H. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large Medicare managed care plan: a case-control study. Am J Geriatr Pharmacother. 2005;3:92-102.
16. Geldmacher DS, Provenzano G, McRae T, et al. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc. 2003;51:937-944.
17. Tariot P, Farlow M, Grossberg G, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donezepil: a randomized controlled trial. JAMA. 2004;291:317-324.
18. Sink K, Holden K, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;294:1934-1943.
19. Cummings J, Schneider E, Tariot P, et al. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil. Neurology. 2006;67:57-63.
20. Cummings JL. Alzheimers disease. N Engl J Med. 2004;351:56-67.
21. Standridge JB. Pharmacotherapeutic approaches to the treatment of Alzheimer's Disease. Clin Ther. 2004;26:615-630.
22. American Medical Association. Practical Guide for the Primary Care Physician on the Diagnosis, Management, and Treatment of Dementia. Chicago, IL: American Medical Association; 1999.
23. Boustani M, Peterson B, Hanson L, et al. Screening for dementia in primary care: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2003;138:927-937.
24. Fillit H, Smith Doody R, Binaso K, et al. Recommendations for best practices in the treatment of Alzheimer's disease in managed care. Am J Geriatr Pharmacother. 2006;4(suppl):S9-S24.
25. National Institute for Health and Clinical Excellence. Donepezil, Rivastigmine, and Galantamine for the Treatment of Alzheimers' Disease. Technology appraisal guidance number TA19. London 2001.
26. Kmietowicz Z. NICE proposes to withdraw Alzheimer's drugs from NHS. BMJ. 2005;330:495.
27. National Institute for Health and Clinical Excellence. Alzheimers' disease - Donepezil, Rivastigmine, and Memantine: Appraisal Consultation Document www.nice.org.uk. London 2005.
28. Mayor S. NICE recommends drugs for moderate Alzheimer's disease. BMJ. 2006;332:195.
29. Pelosi A, McNulty S, Jackson G. Role of cholinesterase inhibitors in dementia care needs rethinking. BMJ. 2006;333:491-493.
30. National Institute for Health and Clinical Excellence. Donepezil, Galantamine, Rivastigmine (review), and memantine for the Treatment of Alzheimer's Disease: NICE Technology Appraisal Guidance TA111, www.nice.org.uk. London November 17, 2006.
31. National Institute for Clinical Excellence. Dementia: NICE Guidance CG042, www.nice.org.uk. London November 22, 2006.
32. Hall JA, Horgan TG, Stein TS, et al. Liking in the physician-patient relationship. Patient Educ Couns. 2002;48:69-77.
33. Kravitz RL, Bell RA, Azari R, et al. Direct observation of requests for clinical services in office practice. What do patients want and do they get it? Arch Intern Med. 2003;163:1673-1681.
34. Kravitz RL, Epstein RM, Feldman MD, et al. Influence of patients' request for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA. 2005;293:1995-2002.
35. Matthews F, McKeith I, Bond J, et al. Reaching the population with dementia drugs: what are the challenges? Int J Geriatr Psychiatry. 2006;29. Epub ahead of print.
36. Hillmer M, Krahn M, Hillmer M, et al. Prescribing patterns for Alzheimer disease: survey of Canadian family physicians. Can Fam Physician. 2006;52:208-209.
37. Wimo A, Winblad B, Aguero-Torres H, et al. The magnitude of dementia occurrence around the world. Alzheimer Dis Assoc Disord. 2003;17:63-67.
38. Boustani M, Callahan C, Unverzagt F, et al. Implementing a screening and diagnosis program for dementia in primary care. J Gen Intern Med. 2005;20:572-577.
39. Olafsdottir M, Foldevi M, Marcusson J. Dementia in primary care: why the low detection rate? Scand J Prim Health Care. 2001;19:194-198.
40. Valcour V, Masaki K, Curb J, et al. The detection of dementia in the primary care setting. Arch Intern Med. 2000;160:2964-2968.
41. Waldemar G, Phung K, Burns A, et al. Access to diagnostic evaluation and treatment for dementia in Europe. Int J Geriatr Psychiatry. 2007;22:47-54.
42. Hinton L, Franz CE, Friend J. Pathways to dementia diagnosis: evidence for cross-ethnic differences. Alzheimer Dis Assoc Disord. 2004;18:134-144.
43. Turner S, Iliffe S, Downs M, et al. General practitioner's knowledge, confidence and attitudes in the diagnosis and management of dementia. Age Ageing. 2004;33:461-467.
44. Adams W, McIlvain H, Geske J, et al. Physicians' perspectives on caring for cognitively impaired elders. Gerontologist. 2005;45:231-239.
45. Post SG, Stuckey JC, Whitehouse PJ, et al. A focus group on cognition-enhancing medications in Alzheimer Disease: disparities between professionals and consumers. Alzheimer Dis Assoc Disord. 2001;15:80-88.
46. Connell CM, Boise L, Stuckey JC, et al. Attitudes toward the diagnosis and disclosure of dementia among family caregivers and primary care physicians. Gerontologist. 2004;44:500-507.
47. Vickrey B, Mittman B, Connor K, et al. The effect of disease management intervention on quality and outcomes of dementia care. Ann Intern Med. 2006;145:713-726.
48. US Preventive Services Task Force. Screening for dementia: recommendation and rationale. Ann Intern Med. 2003;138:925-926.
49. Brodaty H, Low L, Gibson L, et al. What is the best dementia screening instrument for general practitioners to use? Am J Geriatr Psychiatry. 2006;14:391-400.
50. Callahan C, Boustani M, Unverzagt F, et al. Effectiveness of collaborative care for older adults with Alzheimer disease in primary care: a randomized controlled trial. JAMA. 2006;10:2148-2157.